Return
Transforming blood-derived episignatures into cell-type-agnostic classifiers: A shortcut to prenatal episignatures
N
A
P
S
Z
A
D
B
K
J
E
D
E
S
M
R
S
DOI:10.1016/j.ajhg.2026.06.017.png)
Abstract
En 中文
DNA methylation (DNAm) episignatures are stable disorder-specific epigenetic patterns that serve as valuable biomarkers for assessing variant pathogenicity and phenotypic outcomes in neurodevelopmental disorders (NDDs). However, episignatures derived from whole blood are inherently tissue- and cell-type specific, limiting their applicability in prenatal diagnostics. To explore the feasibility of developing episignatures capable of informing variant pathogenicity across tissues and developmental stages, we conducted a proof-of-concept study using Down syndrome, a common NDD caused by trisomy 21 (T21). We generated a blood-derived T21 episignature using a large cohort of 266 samples. Next, we used that episignature and publicly available DNAm data for 850 T21 and control samples across six different pre- and postnatal tissues to train machine-learning models, thereby enabling accurate prediction of T21 status across all tested tissues. Notably, our results show that models trained on postnatal blood-derived signatures as well as other tissues can generate cell-type-agnostic disease-specific patterns. This method also supported integrating well-characterized postnatal episignatures with a limited set of prenatal samples, which generated an episignature capable of accurately classifying prenatal samples. This approach forges a path for cross-tissue DNAm biomarker development and lays the groundwork for a workflow to rapidly integrate episignatures into prenatal diagnostics.
Keywords:
episignatures
DNA methylation signatures
prenatal diagnostics
trisomy 21
machine learning
Down syndrome
neurodevelopmental disorders
tissue-agnostic classifier
Journal
IF:
8.1
Papers:
7.2K
Citations:
3.7W
